Quest Diagnostics Incorporated
$ 238.50
1.13%
06 Aug - close price
- Market Cap 26,030,453,000 USD
- Current Price $ 238.50
- High / Low $ 238.88 / 235.31
- Stock P/E 24.83
- Book Value 68.33
- EPS 9.50
- Next Earning Report 2026-10-20
- Dividend Per Share $3.32
- Dividend Yield 1.42 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.15 %
- 52 Week High 240.13
- 52 Week Low 168.97
About
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Analyst Target Price
$245.87
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-23 | 2026-04-21 | 2026-02-10 | 2025-10-21 | 2025-07-22 | 2025-04-22 | 2025-01-30 | 2024-10-22 | 2024-07-23 | 2024-04-23 | 2024-02-01 | 2023-10-24 |
| Reported EPS | 3.12 | 2.5 | 2.42 | 2.6 | 2.62 | 2.21 | 2.23 | 2.3 | 2.35 | 2.04 | 2.15 | 2.22 |
| Estimated EPS | 2.81 | 2.37 | 2.36 | 2.5 | 2.57 | 2.15 | 2.18 | 2.26 | 2.33 | 1.86 | 2.11 | 2.19 |
| Surprise | 0.31 | 0.13 | 0.06 | 0.1 | 0.05 | 0.06 | 0.05 | 0.04 | 0.02 | 0.18 | 0.04 | 0.03 |
| Surprise Percentage | 11.032% | 5.4852% | 2.5424% | 4% | 1.9455% | 2.7907% | 2.2936% | 1.7699% | 0.8584% | 9.6774% | 1.8957% | 1.3699% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-20 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | 2.85 |
| Currency | USD |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jan 1970 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-22 | 2026-04-20 | 2026-01-28 | 2025-10-20 | None | 2025-04-21 | 2025-01-29 | 2024-10-21 | 2024-07-22 | 2024-04-22 |
| Amount | $0.86 | $0.86 | $0.8 | $0.8 | $0.8 | $0.8 | $0.75 | $0.75 | $0.75 | $0.75 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DGX
2026-08-06 17:01:00
Shares of Quest Diagnostics Inc. rose 1.13% to $238.50 on a strong trading day, outperforming the S&P 500 Index and the Dow Jones Industrial Average, both of which experienced declines. This marks the third consecutive day of gains for the stock.
2026-08-05 18:08:53
Labcorp Holdings (LH) reported strong Q2 revenue and net income, leading to raised full-year 2026 guidance and the launch of new precision oncology and consumer genetic testing offerings. The stock has seen significant gains recently, and is considered approximately 4.4% undervalued based on a fair value estimate of $326.81, driven by anticipated increased test volume and improved operational efficiencies from AI and technology innovations. However, potential risks include revenue pressure from PAMA-related Medicare changes and tough pricing in diagnostics.
2026-08-05 17:55:07
DaVita (DVA) reported adjusted earnings of $4.02 per share in Q2 2026, surpassing the Zacks Consensus Estimate, with revenues of $3.55 billion also exceeding expectations. Despite beating earnings and revenue forecasts and seeing an increase in U.S. dialysis treatments, the company's stock fell in pre-market trading due to a decline in gross and operating margins. DaVita also revised its 2026 outlook, maintaining adjusted EPS guidance but expecting treatment volume near the top end of its previous range.
2026-08-04 05:37:39
Quest Diagnostics (DGX) has increased its 2026 revenue and adjusted earnings guidance, attributing the improved outlook to accelerated testing demand across various channels. While the company's Q2 results exceeded expectations, driven by volume growth, concerns remain regarding the impact of lower-margin partnerships and increased operational spending on future profitability. Investors are advised to consider the balance between organic growth and the potential for integration and cost challenges.
2026-08-03 14:07:24
Quest Diagnostics (DGX) has increased its 2026 revenue and adjusted earnings guidance following strong second-quarter results, driven by accelerated testing demand across various channels. While the company's outlook is improving, investors are cautioned to consider the impact of acquisitions, lower-margin partnerships, and increased spending on operational projects. The stock currently holds a Zacks Rank #2 (Buy) with favorable momentum and balanced style characteristics, despite premium valuation concerns.
2026-08-01 05:39:29
Guardant Health (GH) stock increased by 6.3% despite widening losses, as Q2 revenue grew 44% to US$335 million, driven significantly by Shield testing, which saw a more than threefold increase in revenue and test volumes. The market is focusing on the growth story and Shield momentum, even as the company continues to report substantial net losses and operates with a high P/S multiple of 18.4x. While management raised revenue guidance for the full year and reaffirmed a cash flow breakeven target by the end of 2027, concerns about cash burn and rising operating expenses persist.
